4//SEC Filing
Aunins John G. 4
Accession 0000899243-18-031411
CIK 0001609809other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 4:11 PM ET
Size
9.4 KB
Accession
0000899243-18-031411
Insider Transaction Report
Form 4
Aunins John G.
CTO and EVP of Bioprocess Dev.
Transactions
- Sale
COMMON STOCK
2018-12-17$6.39/sh−14,282$91,313→ 75,250 total - Exercise/Conversion
RESTRICTED STOCK UNITS
2018-12-19−10,000→ 0 total→ COMMON STOCK (10,000 underlying) - Exercise/Conversion
COMMON STOCK
2018-12-19+10,000→ 85,250 total
Footnotes (4)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $6.2100 to $6.5900. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Each restricted stock unit represents right to receive one share of Issuer common stock.
- [F4]These restricted stock units have vested and settled as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018.
Documents
Issuer
Seres Therapeutics, Inc.
CIK 0001609809
Entity typeother
Related Parties
1- filerCIK 0001643756
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 4:11 PM ET
- Size
- 9.4 KB